Antibacterial Haemostatic Gels Market Size & Share, by Product Type (Hematology Testing Kits, Blood Pressure Monitoring Devices, Blood Glucose Monitoring Devices); Animal Type (Cats, Dogs,); End-Use Industry (Homecare, Hospitals, Clinics); Material (Fibrin, Gelatin); Application (General Surgery, Dental Surgery, Veterinary Surgery, Orthopaedic Surgery) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5907
  • Published Date: Mar 22, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Antibacterial Haemostatic Gels Market size is expected to reach USD 3 Billion by the end of 2036, growing at a CAGR of 6% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of antibacterial haemostatic gels was USD 1 Billion. The increase in surgical techniques across the world will primarily drive the antibacterial haemostatic gels market In many of these conditions, the use of surgical and anesthesia care is required, making up a functional, adaptable, and resilient health system. The demand for surgical services in these regions will increase significantly from now until 2030 due to the significant increase in the incidence of cancer, road traffic accidents, and cardiovascular and metabolic diseases in LMICs. The practice of performing manual operations, or surgery, has a rich history dating back to antiquity.

Another reason that will propel the market of antibacterial haemostatic gels by the end of 2036 is the increasing prevalence of wound infection globally. Globally, between 9.1 and 26.1 million people are affected by FUs each year. A recent report raises the population's estimate to 40 to 60 million, citing various factors, including the DFU definition, the surveillance approach, and wound care access. The rise in bacterial resistance to antibiotics is likely to cause an increase in the burden of chronic wound infections worldwide. More than 6.5 million chronic wounds with evidence of bacterial infection are identified annually in the United States of America alone. In addition, several studies have identified the polymicrobial environment as a risk factor for the development of resistance to several antibiotics, including the third-generation cephalosporins used in the Mbarara Regional Referral Hospital for chronic wound infections.

Get more information on this report: Request Free Sample PDF

Antibacterial Haemostatic Gels Market: Growth Drivers and Challenges

Growth Drivers

  • Increasing Investment in Healthcare Worldwide - In 2021, 38% of the population in the OECD countries had a long-standing illness or health issue. Populations are less resilient due to a high prevalence of chronic diseases, which contributes to COVID-19 mortality. Less than 3% of all health expenditures were devoted to prevention, according to the OECD health systems. However, investors must choose more complicated strategies because of the influx of investment. Decision-making models for investing guidance haven't kept up with these rapid changes. In many cases, this has resulted in subpar outcomes. Investors should follow the money to support global health objectives and to support renewed efforts to decolonize global health care. Making decisions more impactful and transparent by starting with improving the way investment decisions are made can help make decisions more effective and transparent.
  • Rise of the Digital Health Globally - Due to their unique understanding of the roles that professionals play in digital health, patients, and providers, medical technology companies are best positioned to take the lead in the digital health revolution. The rising popularity of digital devices, many of which are already available to consumers, is boosting growth. Digital insights will be challenging to use to build a comprehensive Digital Health solution, however, without the appropriate digital foundation to support these businesses internally. The rapid advancement of digital technology and its rapid development have caused change in almost every aspect of human endeavor over the past few decades.
  • Advancement in Technology in Wound Care Components- Dressing technology has changed from a passive to an active role in the modern world. However, understanding the clinical progression that has occurred, even among those treatments that have since been abandoned, would prevent our patients from enjoying the sophisticated dressings they currently wear. As never before, wound care technology is advanced even faster. We can access portable technology, electronic health records, and a variety of exciting products on the antibacterial haemostatic gels market to enable us to gather crucial information at levels that cannot be seen through just eye examination and dressing. We now have access to real-time data on what is happening beneath the skin's surface.


  • High Production and Modification Costs of Antibacterial Haemostatic Gels- Complications like excessive bleeding and the invasion of bacteria are typical symptoms of wounds. To promote faster wound healing, it is crucial to develop wound dressings that stop excessive bleeding and stop bacterial invasion. Topical gels made from sodium alginate (SA) and carbopol were used to fulfill the above-mentioned requirements for wound dressings. Tranexamic acid, a variety of metal-based nanoparticles, and an antifibrinolytic agent were added to the wound dressings. Significant antibacterial activity was observed in the prepared topical gels against Gram-negative bacteria and moderately against Gram-positive bacterial strains. The main obstacle to wound healing is hemorrhage, which can lead to traumatic death and microbial infections. Although this can impede market growth for a little time the constant propelling factors will insist the antibacterial haemostatic gels market grow significantly by the end of 2036.
  • Lack of Knowledge in People About the Disease
  • Stringent Regulatory Policies

Antibacterial Haemostatic Gels Market: Key Insights

Base Year


Forecast Year




Base Year Market Size (2023)

~USD 1 Billion

Forecast Year Market Size (2036)

~USD 3 Billion

Regional Scope

  • North America (North America, Canada, Mexico)
  • Asia Pacific (Japan, China, India, Australia, Others)
  • Europe (Germany, Spain, UK, France, Italy, Russia, Others)
  • Middle East and Africa (South Africa, UAE, Others)
  • Latin America (Brazil, Argentina, Others)
Get more information on this report: Request Free Sample PDF

Antibacterial Haemostatic Gels Segmentation

Product Type (Urinanalysis Testing Kits, Hematology Testing Kits, Blood Pressure Monitoring Devices, Blood Glucose Monitoring Devices)

The urinanalysis testing kits segment will grow the most by the forecast period and will hold almost 38% in the antibacterial haemostatic gels market because of modifying the efficiency, user-friendliness, and patient results. For instance, laboratories 'daily operations heavily rely on single-use plastics, and laboratory testing consumables are typically not susceptible to substitution. To ensure the safety and efficacy of testing protocols as well as the accuracy and reliability of data, laboratories are subject to stringent scientific and regulatory regulations. Life sciences research requires high-quality laboratory consumables, reagents, and validated standard processes. The life science sector has seen an unprecedented need for laboratory supplies related to COVID-19 laboratory work since the pandemic. With suppliers unable to keep up with demand, lab plastic consumables were being used at a faster rate than they were to run RT-PCR tests (consumables like plates and pipette tips). Therefore, this segment will hold immense importance in the transplant monitoring kits market.

End-Use Industry (Homecare, Diagnostic Centres, Hospitals, Clinics)

The hospital segment will have superior growth during the forecast period. It will hold around 50% of the revenue share of the antibacterial haemostatic gels market owing to the increasing extensive range of surgical techniques. More than 3 million deaths are caused by unsafe care each year and roughly 1 in every 10 patients suffer harm in healthcare. Up to 4 out of 100 people in low- to middle-income nations pass away in unsafe care. Global health is a key component of global surgery. The study and practice of global surgery aim to increase access to timely, affordable, and high-quality surgical care. It emphasizes strengthening horizontal health systems by addressing a variety of surgical care issues that improve patient outcomes, particularly in underserved populations.

Our in-depth analysis of the global antibacterial haemostatic gels market includes the following segments:

     Product Type

  • Urinalysis Testing Kits
  • Hematology Testing Kits
  • Blood Pressure Monitoring Devices
  • Blood Glucose Monitoring Devices

     Animal Type

  • Cats
  • Dogs
  • Horses

     End-User Industries

  • Homecare
  • Diagnostic Centres
  • Hospitals
  • Clinics


  • Fibrin
  • Gelatin


  • General Surgery
  • Dental Surgery
  • Veterinary Surgery
  • Cardiovascular Surgery
  • Orthopaedic Surgery

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Antibacterial Haemostatic Gels Industry-Regional Synopsis

North American Market Analysis

The antibacterial haemostatic gels market in the North America region will have the biggest growth during the forecast period with a revenue share of around 43%. This growth will be noticed owing to the rising advancement of healthcare infrastructure in this region. In many ways, the US economy is made up of the healthcare sector. It plays a significant role in people's lives by maintaining their well-being and health. Additionally, its budgetary implications and economic size matter. According to the authors 'calculations and the Bureau of Labor Statistics, the healthcare sector now accounts for 24 percent of government spending and employs 11 percent of American workers.

APAC Market Statistics

The antibacterial haemostatic gels market in the Asia Pacific region will also encounter huge growth during the forecast period and will hold the second position owing to the increasing prevalence of chronic disease in this region. The most populated nation, China, is aging at an unprecedented rate. In 2020, about one in five Chinese people was over 60 years of age. By 2050, this figure, which accounts for 25% of the world's older population, is projected to rise to 1 in 3. Globally, older adults are more susceptible to chronic diseases than younger adults, and older adults are the main cause of premature adult deaths.

Research Nester
Get more information on this report: Request Free Sample PDF

Companies Dominating the Antibacterial Haemostatic Gels Market

    • Pfizer Inc.
      • Company Overview
      • Business Planning
      • Main Product Offerings
      • Financial Execution
      • Main Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • DEXX Laboratories Inc.
    • Medura
    • StopBleed
    • Zoetis Inc
    • Rapid-Seal
    • Coloplast Group
    • Gel-e-life sciences
    • PREVESTDenPro
    • Bio-Chem LLC
    • Smith & Nephew
    • Medtronic
    • B. Braun SE
    • 3M Company


In The News

 Pfizer Inc. declared that the European Commission (EC) has accepted marketing permission for the organization’s 20-valent pneumococcal conjugate vaccine, sold in the European Union under the brand name PREVENAR 20®, for active vaccination for the hindrance of invasive disease, pneumonia and keen otitis media affected by Streptococcus pneumoniae in toddlers, kids, and adolescents from 6 weeks to lower than 18 years of age.

 Pfizer Inc. the transplant organization, declared a leading existence and the fifth successive year as the Distinguished Founder’s Circle Sponsor for the Annual American Society of Transplant Surgeons (ASTS) Winter Symposium organized on January 11 - 14, 2024 in Miami, Florida.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 5907
  • Published Date: Mar 22, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The increase in surgical techniques across the world will majorly drive the market growth of the antibacterial haemostatic gels market.

The market size of the antibacterial haemostatic gels market is expected to get a CAGR of approximately 6% over the forecast period, i.e., 2024-2036.

The major players in the market are Pfizer Inc., DEXX Laboratories Inc., Medura, StopBleed, Zoetis Inc., Rapid-Seal, Coloplast Group, Gel-e-life sciences, PREVESTDenPro, Bio-Chem LLC, Smith & Nephew, Medtronic, B. Braun SE, 3M.

The urinanalysis testing kits segment is anticipated to reap the largest market size with almost 38% by the end of 2036 and demonstrate substantial growth scopes.

The market in the North American region is expected to have the largest market share by the end of 2036 and provide more business opportunities in the future.
Antibacterial Haemostatic Gels Market Report Scope

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying